Whilst the addition of rituximab, a humanized monoclonal antibody to standard CHOP chemotherapy (R-CHOP) has improved the outcomes of DLBCL, the validity of the previously identified prognostic index based on clinical parameters is questioned. It is conceivable that prognostic model may alter with introduction of new therapeutics with differing efficacy and mechanisms of action.
INtRODUCtION
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common form of aggressive Non Hodgkin Lymphoma accounting for 30-35% of all cases. Shipp et al 1 in 1993 established International Prognostic Index (IPI) as a robust prognostic model in patients with aggressive Non-Hodgkin Lymphoma treated with CHOP-like chemotherapy. IPI assigns patients to 4 distinct risk groups based on 5 prognostic factors namely, age >60, Eastern Oncology Group (ECOG) performance status >1, serum LDH>upper limit normal, stage >2 and extra nodal sites >1. Despite it being widely used in clinical trials, there is variability in outcome even within the same risk group.
The age-adjusted IPI (aaIPI) prognostic model utilized 3 factors; performance status, stage and LDH which stratifies patients into 4 risk groups. This prognostic model is applicable for patients less than 60 and has been used predominantly in studies pursuing intensive treatment approaches such as high dose therapy (HDT) and stem cell transplantation (SCT).
Although the addition of rituximab to CHOP chemotherapy has undoubtedly improved the survival outcomes of patients with diffuse large B cell lymphoma [2] [3] [4] [5] [6] , it is conceivable that the validity of IPI is questioned in the era of rituximab. Sehn et al 7 This study evaluated the usefulness of IPI, R-IPI and aa-IPI as a prognostic model in 320 consecutive patients with DLBCL treated with R-CHOP chemotherapy in our institution. We also evaluated for significant prognostic factors determinant of survival in this group of patients.
Patients and methods
Three hundred and twenty consecutive patients with DLBCL who were newly diagnosed and treated with curative intent in our institution from 2003-2008 were included. Medical records of patients with the diagnosis of DLBCL based on current REAL/ WHO classification were reviewed. Our institutional review board approved the study.
Diagnosis, staging and response assessment
Histopathology was centrally reviewed by our hematopathologists. Patients were staged using the modified Ann Arbor Staging criteria based on physical examination, routine laboratory tests, computed tomography (CT) scan of the paranasal sinus, chest, abdomen and pelvis or positron emission tomography (PET) scan and bone marrow biopsies. The IPI was calculated based on 5 adverse risk factors, age >60, Eastern Oncology Group (ECOG) performance status >1, serum LDH>upper limit normal, stage >2 and extra nodal sites >1. Patients were assigned to one of four risk groups based on the number of adverse factors: 0 or 1 to low risk; 2 to low intermediate risk; 3 to high intermediate risk; and 4 or 5 to high risk. Revised IPI (R-IPI) assigns patient to one of three risk groups: 0 to very good risk; 1 or 2 to low risk; and 3, 4, or 5 to high risk.
The age-adjusted international prognostic index (aaIPI) was determined for the patients based on performance status (≤1 versus ≥2), lactate dehydrogenase(LDH) being normal or elevated and stage (1/2 versus 3/4) (0 factors, low risk; 1 factor, low intermediate risk; 2 factors, high intermediate risk; 3 factors, high risk). Other clinical parameters assessed were: B symptoms and bone marrow involvement. Response to treatment was assessed one to three months after completion of planned treatment. In our institution, PET is performed with collaborative CT imaging. Unless contraindicated, intravenous contrast is given to enhance CT imaging. Criteria used to determine the response at the end of treatment was determined based on the imaging modality employed.
tREAtMENt
All patients were treated with R-CHOP chemotherapy consisting of rituximab 375mg/ m² IV day 1, doxorubicin 50mg/m² IV day 1, vincristine 1.4mg/m² IV day 1(cap at 2mg) and prednisolone 50mg/m² orally days 1-5. R-CHOP chemotherapy was administered at a 21-days interval for 6-8 cycles.
ANALysIs
Survival and follow up time were calculated from the date of diagnosis to death or to date when patient was last seen, respectively. The Cox proportional hazards model was utilized to determine the significant prognostic factors for survival. Factors showing significant impact in univariate analysis were tested in a multivariate model for independence of association. Survival curves according to the three prognostic models namely IPI, R-IPI and aaIPI were compared using Kaplan Meier survival analysis. P values from the log rank tests were reported for differences in median survival times. Two sided p value <0.05 were considered statistically significant. All analyses were carried out using STATA version 9.0 (STATA Corporation, College Station, TX, USA). Table 1 shows the demographics and clinical characteristics of 320 patients with DLBCL who received R-CHOP chemotherapy. The median duration of follow up for these patients was 2.70 years.
REsULts
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Among all the patients, the factors affected overall survival (OS) included age, stage of disease, performance status (ECOG), LDH, extranodal, bone marrow involvement, B symptoms, IPI, RIPI and age adjusted IPI ( Table 2 ). All these significant factors affected OS were then included in the multivariate analysis by means of Cox regression, and the factors included in the final model were performance status (P=0.004) and bone marrow involvement (P=0.026), shown in Table 3 . Figure 1 , Figure 2 and Figure 3 , respectively.
Outcomes according to the full International Prognostic Index (IPI) and the age-adjusted International Prognostic Index (aa-IPI)
DIsCUssION
While IPI was predictive for survival for patients treated with CHOP chemotherapy in our patient cohort as previously demonstrated 9 , it was unable to stratify patients treated with R-CHOP chemotherapy into 4 prognostic groups. It appeared IPI only identified patients into 3 main risk groups only. In addition, among patients <60, aa-IPI no longer seem a robust prognostic model. Similar to what was demonstrated by the British Columbia Group 7 , we showed that R-IPI was able to separate patients into 3 different prognostic groups. However, R-IPI was unable to identify a risk group with less than 50% chance of survival.
A recent publication by Ziepert et al 8 maintained the clinical utility of IPI in patients treated with R-CHOP based chemotherapy. The study included data from 3 prospective phase 2/3 trials MInT, RICOVER-60 and MegaCHOEP. The combined analysis included more than 1000 patients. However, the validity of the study in generalizing to patients with DLBCL is questioned given a number of criticisms. Up to 11% of the patients had other forms of aggressive B cell lymphoma other than DLBCL. The studies had differing inclusion criteria. MInt study included only young patients with low risk disease whilst MegaCHOEP study enrolled patients with at least 1 aa-IPI risk factors. RICOVER-60 was essentially a study involving patients >60 with median age of 69 and belonged to all IPI groups. Moreover, the treatment regimens utilized in the studies were different in terms of composition, dosage and scheduling. As such the true utility of IPI in patients with DLBCL treated with R-CHOP chemotherapy remains uncertain.
Despite the conflicting data, it seems evident that all the prognostic models are inadequate in identifying a risk group with less than 50% chance of survival. A more robust prognostic index is necessary in the era of chemo-immunotherapy. the determinants of prognosis and chemoresponsiveness remain unclear.
Diffuse large B cell lymphoma can be classified into subcategories based on gene expression
Two immunohistochemical algorithms have been devised to identify patients falling into the 2 subgroups. Hans et al 12 described the utility of CD10, MUM1 and BCL-6 in distinguishing between GC and ABC phenotype with a concordance rate of 86%. Choi et al 13 subsequently derived a newer algorithm using GCET, CD10, BCL-6, MUM-1 and FOXP-1 that closely approximated the GEP classification with 93% concordance.
Bcl-2, a marker of anti-apoptosis and Bcl-6, a marker of germinal centre expression were identified as independent prognostic markers in patients treated with CHOP chemotherapy alone. Bcl-2 over-expression has been associated with an inferior outcome while Bcl-6 protein expression has been shown to predict a more favorable outcome in patients treated with CHOPlike regimens [14] [15] . However, this differential survival outcome was lost in patients treated in the era of chemo-immunotherapy [16] [17] .
To summarize, there is conflicting data regarding the most robust prognostic index in patients with DLBCL treated with R-CHOP chemotherapy.
Incorporation of molecular markers into clinical parameters should be evaluated, a study we are embarking on.
